This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. When activated and associated with appropriate members of a functional complex, the mammalian target of rapamycin (mTOR) plays an important role in regulation of protein synthesis, cell growth, and proliferation. mTOR inhibitors have the potential to augment the activity of conventional chemotherapeutic drugs, including those frequently used in the treatment of pediatric malignancies. In this Phase I study, the mTOR inhibitor temsirolimus will be administered in combination with irinotecan and temozolomide to patients with recurrent or refractory solid tumors. The irinotecan + temozolomide regimen has activity against solid tumors including Ewing sarcoma and neuroblastoma. Toxicity associated with this regimen has been relatively mild even in heavily pretreated patients. The limited overlap in toxicities associated with temsirolimus and with rinotecan + temozolomide suggests that this three drug regimen is likely to be well-tolerated. Irinotecan (50 mg/m2) and temozolomide (100 mg/m2) will be administered daily x 5 every 3 weeks. Temsirolimus will be administered on days 1 and 8 of each 3 week cycle. The starting dose of temsirolimus will be 15 mg/m2, and the dose of this agent will be escalated stepwise to a maximum dose of 35 mg/m2 on Days 1 and 8. Because the primary objective of the study is to determine the maximum dose of temsirolimus that can be administered in combination with widely used doses of irinotecan and temozolomide, doses of the irinotecan and temozolomide will not be escalated during this trial. If the administration of temsirolimus on Days 1 and 8 is not well tolerated when given in combination with irinotecan and temozolomide, then temsirolimus will be administered once per cycle only. Patients will be accrued to dose levels in cohorts of 2 to 6 using the Rolling Six Phase I trial design. There will be no intrapatient dose escalation. Toxicity will be graded using the CTCAE version 4.0 and response will be assessed using RECIST criteria. Optional laboratory analyses of modulation of mTOR pathway signaling will be conducted using tumor-containing bone marrow samples from consenting patients.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000188-47
Application #
8356756
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2010-12-01
Project End
2011-11-30
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
47
Fiscal Year
2011
Total Cost
$3,562
Indirect Cost
Name
Baylor College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Hunsaker, Sanita L; Garland, Beth H; Rofey, Dana et al. (2018) A Multisite 2-Year Follow Up of Psychopathology Prevalence, Predictors, and Correlates Among Adolescents Who Did or Did Not Undergo Weight Loss Surgery. J Adolesc Health 63:142-150
Lanzieri, Tatiana M; Chung, Winnie; Leung, Jessica et al. (2018) Hearing Trajectory in Children with Congenital Cytomegalovirus Infection. Otolaryngol Head Neck Surg 158:736-744
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Michalsky, Marc P; Inge, Thomas H; Jenkins, Todd M et al. (2018) Cardiovascular Risk Factors After Adolescent Bariatric Surgery. Pediatrics 141:
Lau, Chantal (2018) Breastfeeding Challenges and the Preterm Mother-Infant Dyad: A Conceptual Model. Breastfeed Med 13:8-17
Gururangan, Sridharan; Reap, Elizabeth; Schmittling, Robert et al. (2017) Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). Cancer Immunol Immunother 66:1589-1595
Lanzieri, T M; Leung, J; Caviness, A C et al. (2017) Long-term outcomes of children with symptomatic congenital cytomegalovirus disease. J Perinatol 37:875-880
El-Hattab, Ayman W; Zarante, Ana Maria; Almannai, Mohammed et al. (2017) Therapies for mitochondrial diseases and current clinical trials. Mol Genet Metab 122:1-9
Jin, Haoxing Douglas; Demmler-Harrison, Gail J; Coats, David K et al. (2017) Long-term Visual and Ocular Sequelae in Patients With Congenital Cytomegalovirus Infection. Pediatr Infect Dis J 36:877-882
Oh, Sam S; Du, Randal; Zeiger, Andrew M et al. (2017) Breastfeeding associated with higher lung function in African American youths with asthma. J Asthma 54:856-865

Showing the most recent 10 out of 459 publications